Systasy Bioscience GmbH, a Munich-based biotech company, uses advanced barcoding technologies and next-generation disease modeling to facilitate drug discovery in complex diseases. Systasy’s innovative and proprietary technologies provide a fast and cost-effective approach to mapping disease pathways from the cellular level to the patient cohort level to enable next-generation medicine. Systasy’s barcoding technology uses molecular barcodes to track different entities within one experiment. These entities include activities of targets and cellular pathways, cell types and patient material, as well as technical features such as biological replicates, wells, and plates. When applied to next-generation stem cell-derived disease models, Systasy’s barcoded and cell-based profiling assays enable multiplexed and scalable drug screening in early-stage drug discovery.